Rafferty Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-306,233
| Closed | -$5.68M | – | 1109 |
|
|
2023
Q3 | $5.68M | Sell |
306,233
-106,041
| -26% | -$1.2M | 0.03% | 364 |
|
|
2023
Q2 | $4.56M | Buy |
412,274
+151,849
| +58% | +$2.12M | 0.03% | 434 |
|
|
2023
Q1 | $3.5M | Sell |
260,425
-5,492
| -2% | -$95K | 0.02% | 474 |
|
|
2022
Q4 | $3.29M | Buy |
265,917
+40,313
| +18% | +$571K | 0.03% | 462 |
|
|
2022
Q3 | $3.15M | Buy |
225,604
+72,411
| +47% | +$1.17M | 0.03% | 407 |
|
|
2022
Q2 | $2.12M | Sell |
153,193
-74,650
| -33% | -$1.2M | 0.02% | 449 |
|
|
2022
Q1 | $3.71M | Sell |
227,843
-31,996
| -12% | -$501K | 0.02% | 448 |
|
|
2021
Q4 | $4.23M | Buy |
259,839
+112,239
| +76% | +$1.89M | 0.02% | 448 |
|
|
2021
Q3 | $2.19M | Buy |
147,600
+26,609
| +22% | +$426K | 0.02% | 616 |
|
|
2021
Q2 | $2.42M | Sell |
120,991
-37,601
| -24% | -$745K | 0.02% | 622 |
|
|
2021
Q1 | $3.66M | Buy |
158,592
+128,237
| +422% | +$3.57M | 0.03% | 371 |
|
|
2020
Q4 | $750K | Sell |
30,355
-17,226
| -36% | -$571K | 0.01% | 590 |
|
|
2020
Q3 | $1.97M | Buy |
47,581
+34,877
| +275% | +$1.6M | 0.02% | 421 |
|
|
2020
Q2 | $609K | Buy |
12,704
+8,846
| +229% | +$683K | 0.01% | 666 |
|
|
2020
Q1 | $243K | Sell |
3,858
-29,007
| -88% | -$2.61M | 0.01% | 484 |
|
|
2019
Q4 | $4.07M | Sell |
32,865
-61,232
| -65% | -$5.48M | 0.06% | 160 |
|
|
2019
Q3 | $6.24M | Buy |
94,097
+31,921
| +51% | +$2.14M | 0.1% | 120 |
|
|
2019
Q2 | $4.95M | Buy |
62,176
+13,041
| +27% | +$1.17M | 0.09% | 168 |
|
|
2019
Q1 | $5.5M | Buy |
+49,135
| New | +$5.37M | 0.09% | 123 |
|
Rafferty Asset Management's ICPT Position: Q4 2023 in Review
Rafferty Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 306,233 shares — an estimated $5.68M sold.
Rafferty Asset Management first reported a position in ICPT in Q1 2019 and held it in 19 quarters. The position peaked at $6.24M in Q3 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Rafferty Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Rafferty Asset Management sold 306,233 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $5.68M.
- Rafferty Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 19 quarters.
- Rafferty Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $6.24M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.